Agreement with Kyowa Hakko Kirin providing Lundbeck with exclusive rights to develop and commercialise the adenosine A2a antagonist KW-6356. Lundbeck will also have the right to further select compounds as either back-up or additional indication compounds 'read the full Lundbeck-Kyowa Hakko Kirin release (Link no longer available)